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Abst rac t
Sleepiness is a physiological function and can be defined as an increased propensity to fall asleep. However, excessive sleepiness
or hypersomnia refer to an abnormal increase in the likelihood of falling asleep, dozing off or having sleep attacks when sleep is
not desired. The main causes of excessive sleepiness are chronic sleep deprivation, obstructive sleep apnea syndrome, narcolepsy,
movement disorders during sleep, circadian rhythm sleep disorders, use of illicit/prescription drugs and idiopathic hypersomnia.
Social, familial, work, and cognitive impairment are among the consequences of hypersomnia. An increased risk of accidents has
also been reported. The treatment of excessive sleepiness includes treating the primary cause, when identified. Sleep hygiene for
sleep deprivation, continuous positive airway pressure for sleep apnea, dopaminergic agents and exercises for sleep-related
movement disorders and phototherapy or melatonin for circadian disorders, as well as the use of stimulants in general, are the
treatment modalities of choice.
Keywords: Sleep disorders; Disorders of excessive somnolence; Chronobiology disorders; Narcolepsy; Restless legs syndrome;
Sleep apnea, obstructive
Resumo
A sonolência é uma função biológica, definida como uma probabilidade aumentada para dormir. Já a sonolência excessiva (SE),
ou hipersonia, refere-se a uma propensão aumentada ao sono com uma compulsão subjetiva para dormir, tirar cochilos involuntários
e ataques de sono, quando o sono é inapropriado. As principais causas de sonolência excessiva são a privação crônica de sono
(sono insuficiente), a Síndrome da Apnéia e Hipopnéia Obstrutiva do Sono (SAHOS), a narcolepsia, a Síndrome das Pernas
Inquietas/Movimentos Periódicos de Membros (SPI/MPM), Distúrbios do Ritmo Circadiano, uso de drogas e medicações e a
hipersonia idiopática. As principais conseqüências são prejuízo no desempenho nos estudos, no trabalho, nas relações familiares
e sociais, alterações neuropsicológicas e cognitivas e risco aumentado de acidentes. O tratamento da sonolência excessiva deve
estar voltado para as causas específicas. Na privação voluntária do sono, aumentar o tempo de sono e higiene do sono, o uso do
CPAP (Continuous Positive Airway Pressure) na Síndrome da Apnéia e Hipopnéia Obstrutiva do Sono, exercícios e agentes
dopaminérgicos na Síndrome das Pernas Inquietas/Movimentos Periódicos de Membros, fototerapia e melatonina nos Distúrbios
do Ritmo Circadiano, retiradas de drogas que causam sonolência excessiva e uso de estimulantes da vigília.
Descritores: Distúrbios do Sono; Sonolência Excessiva; Distúrbios do ritmo circadiano; Narcolepsia; Síndrome das pernas
inquietas; Apnéia do sono tipo obstrutiva
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I n t r oduc t i on
Excessive sleepiness (ES) and sleep disorders (SDs) are
prevalent in our society today. Recent information shows serious
consequences of these problems. In 1990 in the USA,
200,000 car accidents were caused due to motorists falling
asleep at the wheel. On the other hand, one-third of all fatal
accidents involving truck drivers are related to ES while driving.
Great disasters, such as: the Exxon Valdez, Bhopal, the
Challenger, Chernobyl and Three Mile Island have been
associated with lack of judgment and poor performance related
to fatigue. Forty million Americans suffer from chronic SDs,
95% of which are neither properly diagnosed nor treated. In
1990, the costs directly related to ES and SDs in the USA
were 15.9 billion dollars.1
De f i n i t i on
Sleepiness is a biological function, defined as an increased
likelihood of falling asleep. However, ES, or hypersomnia,
refers to an increased propensity to fall asleep and a subjective
compulsion to sleep, as well as a tendency to take involuntary
naps or suffer sleep attacks when sleep is not desired.2 From
2% to 5% of the population is affected by ES, which has
consequences for study and work, as well as for family and
socia l  re lat ions.  In addi t ion, ES can resul t  in
neuropsychological changes, cognitive changes and an
increased risk of accidents.
The symptom known as ES has long been attributed to
clinical depression, apathy or lassitude, as well as to negative
personality traits. True ES, in which physiological sleepiness
is not present, is not attributable to any particular condition. It
should be distinguished from fatigue and apathy, conditions
related to a number of physical and psychiatric illnesses
(multiple sclerosis, lupus, cancer, infections, Parkinson's
disease, cerebral vascular accidents, chronic fatigue syndrome,
fibromyalgia, depression, etc).3 Fatigue is referred to as
tiredness, lack of energy and exhaustion. It is generally induced
by excessive activity and alleviated by rest. On the other hand,
ES is referred to as a decreased capacity for performing
physical and mental work, being, many times, incompletely
relieved with rest or sleep, as well as being normally associated
with SDs.4 These conditions often coexist in the same patients,
despite being distinct clinical entities. The presence of fatigue
or ES may indicate a psychiatric illness or even represent a
worse prognosis of such an illness.
Cause s
The main causes of ES are chronic sleep deprivation
(insufficient sleep), obstructive sleep apnea-hypopnea syndrome
(OSAHS), narcolepsy, restless legs syndrome (RLS)/periodic
limb movements in sleep (PLMS), circadian rhythm disorders,
use of illicit/prescription drugs and idiopathic hypersomnia.5
1.  Chronic  s leep depr ivat ion
It is believed that, with the advent of electricity and
consequently the use of televisions and computers, as well as
higher demands on working hours, studies and social
commitments,  people are s leeping less and, as a
consequence, complaining of ES.
2.  OSAHS
This syndrome affects 2% to 4% of the population, especially
overweight men over the age of 40.6 It is defined as recurrent
episodes of upper airway obstruction during sleep, which
usually results in desaturation of oxyhemoglobin and, in ca-
ses of prolonged events, it results in hypercapnia. This
obstruction may be partial (hypopnea) or total (apnea). The
events end upon awakening.7 The diagnosis of OSAHS is made
based on clinical and polysomnographic criteria: 1) excessive
daytime sleepiness unexplained by other causes and; 2) two
or more of the following symptoms and signs not explained by
other conditions: asphyxia or difficulty in breathing during sleep,
recurrent nocturnal awakenings, sensation of nonrestful sleep,
daytime fatigue and difficulty in concentrating; 3) five or more
obstructive respiratory events (apneas and hypopneas and
awakenings related to respiratory efforts) per hour of sleep,
recorded during all-night polysomnography.7 The severity of
OSAHS is based on the degree of ES and on the number of
obstructive events per hour of sleep.7
3.  Narco lepsy
Narcolepsy is a rare condition (1/1000 individuals),
presenting a higher incidence among individuals between 18
and 25 years of age, whose symptoms may precede the
diagnosis by 20 years, on average.5 It may present classically
as the following signs and symptoms: ES, cataplexy (loss of
muscle tonus), sleep paralysis, hypnagogic hallucinations and
fragmented sleep. It may be monosymptomatic, expressing itself
only through ES, or oligosymptomatic, expressed through ES
and cataplexy. The degree of ES is variable and the cataplexy
attacks may involve several muscle groups. These are triggered
by emotions, of which laughing is the most common.8 There
is a genetic predisposition, meaning that 85% to 90% of the
patients with narcolepsy have a specific allele of HLA II (12%
to 28% of the general population has this allele). The presence
of the allele is neither necessary nor sufficient. There is a
family occurrence (1% to 4%), a concordance between twins
of 17% to 25% and a deficiency in orexin (hypocretin) has
been described in the liquor of these patients. Other immune,
sel f- immune and environmental factors (stress, s leep
deprivation, conflicts and family loss) may be involved.9 In the
polysomnography, we found decreased latency for sleep onset
and for REM sleep, as well as frequent awakenings. In the of
multiple sleep latency test (MSLT), we observed average latency
values less than or equal to 5 minutes and two or more sleep
onsets in REM sleep in the five data sets.10
4. Restless Legs Syndrome/Periodic Limb Movements
in S leep
The PLMS phenomenon occurs more frequently in individuals
over the age of 30, and the prevalence in this age range is
5%. For those over the age of 60, the prevalence reaches as
high as 44%. Concomitant ES occurring as a consequence is
seen in 11% of the patients. Of the patients with RLS, 80%
present PLMS, although few individuals with PLMS have RLS.11
The diagnostic criteria for PLMS include: insomnia, ES, limb
movements are reported by the partner (even in asymptomatic
patients), stereotyped limb movements with hallux extension
(bending the legs at the knee and hip), polysomnography
showing five or more episodes per hour of PLMS sleep (muscle
contraction 25% above resting value, in a sequence of four or
more movements, with a duration of 0.5 to 5 seconds each at
5- to 90-second intervals).10 The diagnostic criteria for RLS
are clinical, referred to as an uncomfortable feeling in the
legs, which leads to an irresistible urge to move them. It
worsens with rest or sleep and improves with movement.10
The prevalence of RLS ranges from 5% to 15%. It is possible
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that RLS and PLMS are related to conditions such as
pregnancy, neuropathy, uremia, iron-deficiency anemia,
withdrawal of benzodiazepines, use of tricyclic antidepressants
and use of lithium.11
5.  C i rcadian Rhythm Disorders
Circadian rhythm disorders may lead to ES, especially if the
individuals affected are obliged to synchronize with the
environment.
In the delayed sleep phase syndrome, sleep is late compared
to real time, resulting in difficulty in initiating sleep and in
waking within the desired time frame. In the advanced sleep
phase syndrome, the opposite is observed; sleep is early
compared to real time, leading to ES in the early evening and
early awakening. In the non-24 hour sleep-wake cycle
syndrome, which is common among the blind, individuals
tend to sleep at irregular times each day. In jet-lag syndrome,
individuals who engage in transmeridian travel, crossing many
time zones rapidly, have difficulty in maintaining sleep and
present symptoms of ES, gastrointestinal disorders and
psychosomatic disorders. In the shift-work sleep disorder,
symptoms such as ES and fatigue, as well as gastrointestinal,
cognitive and performance alterations, affect people who invert
sleeping time due to night work.12-13
6.  Drugs and medicat ion
There is a possibility that ES is caused by the use of various
medicat ions,  such as hypnot ics,  ant iconvulsants,
antidepressants, antihistamines, lithium, antipsychotics,
antiparkinsonian drugs, and cardiovascular drugs.14
7.  Id iopath ic  hypersomnia
Idiopathic hypersomnia is an illness of the central nervous
system in which prolonged periods of sleep occur (one or two
additional hours) with subsequent ES. It principally affects
individuals of approximately 25 years of age. Polysomnography
is normal and sleep onset latency is normally less than 10
minutes, and there is an increase in the amount of NREM
sleep. The latency for REM sleep is normal. The MSLT shows
a mean latency of less than 10 minutes and of less than 2
minutes for sleep onset in REM sleep.10
Consequences
From the point of view of cognitive performance, many are
the alterations that may be directly related to losses caused by
SDs, including: difficulty in fixing and maintaining attention;
memory loss; loss in the ability to plan strategically; mild motor
loss (more related to fine motor skills such as agility and
precision); difficulty in controlling impulses and clouded
thought. Our mental functioning is totally integrated; if there
is loss in any one function, the performance in another may
be affected to a greater or lesser degree.15 Several of these
functions are found to be lower in fatigue and ES situations.
One of the most apparent changes of the increase in
sleepiness is its effect on the state of alertness. The number
of lapses of attention, for instance, evaluated in a test of
sustained attention model, practically increases in a linear
manner, combined with the number of vigilance hours. The
frequency of lapses of attention also accompanies circadian
fluctuation of body temperature throughout the day, in such a
way that a significant reduction in alertness occurs in moments
close to the minimum value of body temperature during the
night.16 In addition to the circadian expression in alertness,
some sleep components, with their duration and quality, are
controlled by the circadian system and, therefore, depend on
the moment that the system occurs during the day. In gene-
ral, sleep during the day is shorter and more fragmented when
compared to nocturnal sleep, representing a challenge for
those who need to invert the sleep and vigilance pattern, as is
the case of shift workers.17-19 The higher frequency of car
accidents considered the result of sleepiness during the night
and the higher proportion of accidents during night shift confirm
the risks associated to ES resulting from the interaction between
sleep restriction and circadian disorganization.17,20-22 In Brazil,
the contribution of sleepiness in car accidents may be inferred
by the study of de Mello et al:23 16% of the bus drivers
interviewed confessed having fallen asleep while driving,
whereas more than half of these drivers (58%) admitted to
know another driver who slept while driving. Furthermore,
among SDs, the obstructive sleep apnea syndrome is an
important cause of ES and also frequently associated with an
increased risk of accidents.24-27 In this context, Brazilian
estimates show that both snoring and sleep apnea are common
among split-shift workers.18-19,23
According to this panorama, sleep restriction, circadian
disorganization and SDs may act in a synergic manner,
facilitating the occurrence of severe sleepiness and accidents.
The importance of recognizing these factors as critical both to
private and to public safety is evident, as well as considering
the adoption of strategies as a priority.
Invest igat ion o f  excess ive s leepiness
Many procedures may be used for appropriate investigation
of ES, among which are: clinical evaluation, keeping a sleep
diary, subjective measurements and objective measurements.
During clinical evaluation, collecting a sleep history is
essential for identifying the nature of the problem. The sleep-
wake patterns of the patient should be evaluated, considering
weekends and holidays, including an interview with the
partner, in addition to the symptoms over a 24-hour period.
The presence o f  psychia t r ic  and psychopatho log ica l
disorders, as well as of clinical or neurological diseases,
should be invest igated.  A lcohol  or  drug use and i ts
relationship with sleep patterns and ES should also be
investigated. Information on type, dose and time of ingestion
should be included in the investigation.
Sleep diaries are important instruments in the evaluation of
ES. Two weeks of evaluation are indicated for the observation
of circadian rhythms and sleep hygiene disorders. In addition
to these, the determination of the presence of naps may also
help in the characterization of sleep patterns. Sleep diaries
should include bedtimes and rising times, as well as sleeping
and waking times, sleep quality, awakenings during the night
(time and duration), naps, the use of medication, etc.
Subjective measures may be used for evaluating the feeling
of ES at a given moment or in daily situations. These are
based on standardized questionnaires which should be
completed by the patient. However, this may present a problem
when the patient is unaware of his condition or has inaccurate
perceptions regarding ES. Many sleepiness scales have been
made available in the literature. However, the most frequently
used are the Stanford Sleepiness Scale (SSS),28 Karolinska
Sleepiness Scale (KSS)29 and Epworth Sleepiness Scale
(ESS).30 The SSS and KSS allow the evaluation of ES at the
moment of application. The disadvantage is the fact that ES
may vary from one moment to another. In these scales, the
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patient must choose between the different descriptions and
levels of ES (from totally awake to totally asleep) which best
define his current state. The ESS, on the other hand, evaluates
ES in several active and passive situations. The situations
include: sitting and reading; watching TV; sitting in a public
place; being a train, car or bus passenger (for one hour, non-
stop); laying down in the afternoon to rest; sitting and talking
to someone; sitting calmly after lunch, with no alcohol; while
driving, but stuck in traffic for a few moments. The patient
reports the chance of falling asleep in each of the situations
described, scoring from 0 (no chance) to 3 (high chance).
The reference values are: normal ES: from 0 to 6; limited ES:
from 7 to 9; mild ES: from 10 to14; moderate ES: from 15 to
20; severe ES: over 20.31 The ESS is simple and easy to apply
and it is able to discriminate between patients with some SDs
and normal individuals.32 It is relatively stable when reapplied
in healthy controls, as well as being able to detect variations
of ES in patients submitted to treatment, especially in patients
with obstructive sleep apnea.33 Some problems may be related
to the ESS, such as ambiguity in some situations presented.
Furthermore, ES may vary within the same situation, depending
on the duration or moment of the day in which it occurs.
Some of these limitations may be partly responsible for the
low correlation found between the ESS and the objective
evaluation of ES using the MSLT.34-35
Polysomnography, the MSLT and the Maintenance of
Wakefulness Test (MWT) may be used for the objective
evaluation of ES. As well as allowing the recording of multiple
physio logical  var iables dur ing one night  of  s leep,
polysomnography is an essential tool for the evaluation of
nocturnal sleep patterns and diagnosis of SDs.36-37 It should
be indicated for patients reporting ES, except for those with
ES clearly associated with sleep deprivation or use of
medication. The gold standard for the objective quantification
of ES is the MSLT, the most utilized test for this matter. Both
the MSLT and the MWT evaluate sleep onset in 4 or 5
polygraphic recordings per day, at 2-hour intervals, normally
following nocturnal polysomnography. Whereas the MSLT
evaluates the length of time the patients takes to sleep in a
sleep-inducing situation and to have early REM sleep (essential
for the diagnosis of narcolepsy), the MWT measures the ability
to stay awake. This may explain why the correlation between
the two tests is low (0.41).38 On the other hand, MWT better
reflects ES after treatment.39 The minimum parameters for sleep
staging, as proposed by Rechtschaffen & Kales, are used for
recording in both tests (1968).40 The set up includes the
recording of the electroencephalogram (EEG), electro-
oculogram and submental electromyogram. The EEG must
include electrodes in the central regions, referenced by the
mastoid or contralateral earlobe (C3-A2 and C4-A1). The
inclusion of electrodes in the occipital regions (O1 and O2)
may be very useful for the identification of sleep onset (alpha
rhythm extinction). The individual should be awakened at the
usual time, put on normal and comfortable clothes and have
breakfast, avoiding caffeinated substances. At approximately 2
hours (from 1.5 to 3 hours) after arousal, the first record is
made. During the intervals between the tests, the patient should
leave the room, not being allowed to sleep or take any stimulant
substance. In the case of smokers, it is advised not to smoke
30 minutes prior to the start of each record. The most essential
differences between the tests are as follows: in the MSLT, the
record should always be made when the patient is laying
comfortably in the recording room, a si lent and dark
environment. Prior to the initiating of the recording, the patient
is instructed not to resist sleep; in the MWT, the record is
made when the patient is sitting in a comfortable chair in a
low-light environment and instructed to resist sleep. The sleep
onset criteria (Table 1) and the normative values for the MSLT
depend on the approach of the researcher, although average
latencies of less than 5 minutes are considered abnormal
(Table 2). The normative values for the MWT are more well-
established: in a 20-minute test, sleep latency of less than 11
minutes is considered abnormal.41 In the attempt to avoid false
negatives and false positives, some precautions must be taken.
The patient may be instructed to sleep and wake at regular
and consistent times for one to two weeks prior to the exam.
A sleep diary detailing sleep times, use of stimulants, use of
alcohol and nap taking may be useful. Medication acting on
the central nervous system (antidepressants, benzodiazepines,
hypnotics, stimulants, alcohol, etc.) should be withdrawn,
and i t  is essential to wait at least 14 days after the
discontinuation of medication before administering the MSLT.
These measures aim to avoid the rebound of any sleep phase,
as well as to avoid a false-negative result if the individual is
using any drug that alters sleep architecture (for example,
antidepressants suppress REM sleep). The occurrence of
REM sleep after 10-15 minutes of sleep onset is defined as
early REM sleep (sleep-onset REM period). At least two
recorded incidents of early REM sleep are required for the
diagnosis of narcolepsy.
Considering the pros and cons of the various instruments
currently available in the literature, all may be used with
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reasonable safety for the evaluation of ES in different types of
patients and approaches.
Trea tmen t s
The treatment of ES must be specific for the underlying
cause. The inadequate amount of sleep must be approached
with measures of sleep hygiene, so that the amount and quality
of sleep may be recuperated.
For OSAHS, general measures such as losing weight,
avoiding alcohol and sedatives, giving preference to the late-
ral decubitus, treating otorhinolaryngologic diseases and treating
gastroesophageal reflux, are required.46 The main treatment for
OSAHS is continuous positive airway pressure, which has been
shown to improve excessive daytime sleepiness, systemic arte-
rial hypertension, quality of life and cognition.47 The use of devices
that promote the advance of the jaw and of surgeries are
reserved for certain types of patients.46
The treatment of narcolepsy includes sleep hygiene
measures,  programmed naps and cont inuous use of
medication, among which are stimulants such as modafinil,
methylphenidate, dexamphetamines and pemoline. These will
be approached later. The use of antidepressants is more recent.
Studies involving the use of sodium oxybate for the treatment
of cataplexy are currently being conducted.5,8,14
Regular aerobic exercises, iron supplementation when
needed and withdrawal of medications that exacerbate
periodic movements are recommended in RLS/PLMS. Specific
pharmacological treatment consists of the use of dopaminergic
agents (levodopa, pergolide) and dopaminergic agonists
(pramipexo le ,  rop in i ro le ) ,  op io ids ,  carbamazepine,
clonazepam and clonidine.5,11
For the treatment of circadian rhythm disorders, sleep
hygiene, phototherapy (2000 to 10,000 lux, at t imes
predetermined by the type of disorder) and use of melatonin
(0.5 to 10 mg) have been recommended.5,12
Idiopathic hypersomnolence is treated with stimulants.5 The
stimulants include a class of several medications including
amphetamine (2.5 mg/day), methylphenidate (5 mg/day),
pemoline (discontinued due to risk of hepatic insufficiency)
and, more recently, a new stimulant, more specific for
alertness, modafinil (100 to 300 mg/day). The main effects of
this class of medication are decreased sleep time and increased
alertness. Individuals under the effect of these drugs present
better performance, less fatigue and decreased sleepiness, as
well as improved mood and cognition. The main collateral
e f fects  are insomnia,  euphor ia,  anorex ia,  headache,
increased arterial pressure and higher cardiac frequency.
Both expected and undesired effects depend on the type of
medication, dose, patient age and previous state of health.
The medicat ion is  contra- indicated for  pat ients wi th
g laucoma,  uncompensated card iovascu la r  d isease,
hyperthyroidism, use of monoamine oxidase inhibitors,
psychoactive states, uncontrolled convulsions, etc.5,14
Modafinil has been used as the treatment of choice in
narcolepsy and idiopathic hypersomnia.48 However, this
medication has been used in several studies to treat sleepiness
and fatigue related to neurological and psychiatric diseases,
attention deficit, split-shift work49 and residual sleepiness in
OSAHS under treatment with continuous positive airway
pressure.50-51 This medication has advantages over others in
that it affects more specific areas of the brain, causing less
mood alteration, little cardiovascular change, low tolerance
and minimal dependence.
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